Tumor vasculature‐targeted TNF immunocytokines are being developed, most notably NGR‐TNF and L19‐TNF, which are currently in phase II/III clinical trials for, respectively, mesothelioma and melanoma (Danielli et al, 2015a; Gregorc et al, 2018). This evidence concerns the gene RTN4R and mesothelioma.